CambPharma Solutions

CambPharma Solutions is a Cyprus-based pharmaceutical regulatory and sponsorship entity affiliated with Cambridge Regulatory Services. The company appears to function primarily as an EU-based vehicle for regulatory affairs, orphan drug designation, paediatric investigation plan submissions, and related market-access support for pharmaceutical clients that lack their own EU presence. Public regulatory records show CambPharma Solutions acting as the orphan designation holder or applicant for products including copper histidinate (CUTX-101) for Menkes disease and as the EMA applicant for paediatric filings related to umbralisib and ublituximab. It does not appear to be a traditional drug-discovery biotech with an internal R&D pipeline; rather, it supports development and regulatory execution for client or partner assets.